Better survival after breast-conserving therapy compared to mastectomy when axillary node status is positive in early-stage breast cancer: a registry-based follow-up study of 6387 Norwegian women participating in screening, primarily operated between 1998 and 2009
| Autor: | Rolf Kåresen, Jan F. Nygård, Olaf Johan Hartmann-Johnsen, Ellen Schlichting |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty Survival medicine.medical_treatment lcsh:Surgery Breast Neoplasms Norwegian Mastectomy Segmental lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine Breast cancer Surgical oncology Internal medicine medicine Humans Registries Stage (cooking) skin and connective tissue diseases Breast conserving therapy Mastectomy Aged business.industry Proportional hazards model Research Hazard ratio lcsh:RD1-811 Middle Aged Prognosis medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens language.human_language Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Axilla Cohort language Female Surgery business Follow-Up Studies |
| Zdroj: | World Journal of Surgical Oncology, Vol 15, Iss 1, Pp 1-10 (2017) World Journal of Surgical Oncology |
| ISSN: | 1477-7819 |
| DOI: | 10.1186/s12957-017-1184-6 |
| Popis: | Background Recent registry studies on early-stage breast cancer have shown better survival rates when women underwent breast-conserving therapy (BCT) compared with mastectomy (MTX). The aim of this study is to investigate women participating in screening, in all four stages of early breast cancer (T1N0M0, T2N0M0, T1N1M0, and T2N1M0), as to whether there is a survival benefit when women undergo BCT compared to MTX. Method A cohort of 6387 women aged 50–69, with primary-operated breast cancer from January 1998 to December 2009, participating in screening and followed-up until the end of 2010. Life tables were calculated by stages (pT1N0M0, pT2N0M0, pT1N1M0, and pT2N1M0), surgery groups (BCT and MTX), and screening detection (first screening, later screening, or interval cancer). Cox regression was used to calculate hazard ratios (HR) between BCT and MTX in crude and adjusted analyses. Results In stage T1N1M0, women who underwent MTX had an HR of 2.91 (95% CI 1.30–6.48) for breast cancer death compared to women who underwent BCT, after adjusting for screening detection, years of diagnosis, age at diagnosis, histology, grade, and hormone receptor status. For all other TNM categories of early breast cancer, there was no difference in survival. 10-year breast cancer-specific survival (BCSS) in T1N0M0 was 98% for women undergoing BCT and 96% for women undergoing MTX. 10-year BCSS in T1N1M0 was 97% for women undergoing BCT and 89% for women undergoing MTX. Conclusions For women participating in screening, there is a benefit of BCT over MTX in stage T1N1M0. No such effects were observed in the other early stages of breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|